The unique fibrosis model offered by InfiCure is attracting international attention. Last month the startup signed their first contract for a full-service preclinical pilot study to test two substances for an american client in Boston. The trial i currently underway, with all lab work beeing done on location in Umeå. […]

InfiCure Bio, a life-science company in the field of inflammation and fibrosis, has characterized a new preclinical model that spontaneously develops chronic inflammation and fibrosis in multiple organs. The model is called the non-obese diabetic inflammation and fibrosis (N-IF) mouse and you can read all about it here. […]

Life science-företaget Inficure Bio har som vision att bli världsledande inom tester av anti-fibrotiska läkemedel. Företaget har tagit fram en modell som spontant utvecklar fibros i bland annat lever, njure och lunga. […]

Umeåföretaget InfiCure Bio siktar på att bli världsledande på sitt område men behöver mer kapital. – Vi vill få in en investerare som kan komma in med kapital men gärna med kompetens också, säger Sofia Mayans som är VD för InfiCure Bio. […]